Product
Chidamide+venetoclax
1 clinical trial
1 indication
Indication
Acute Promyelocytic LeukemiaClinical trial
Multi-center Phase II Prospective Study for the Treatment of Chidamide and Venetoclax in Patients With All-trans Retinoic Acid (ATRA) and Arsenic (As) Resistant Acute Promyelocytic Leukemia (APL)Status: Recruiting, Estimated PCD: 2025-01-01